The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.

Inclusion Criteria:

• self-identified as Asian/European ancestry
• generally healthy with approved lab values for CBC,HFP,RFP, and uric acid
• Subjects with the ABCG2 genotype, homozygous, heterozygous or homozygous for the major allele of rs2231142 will be recruited

Exclusion Criteria:

• vascular disease
• renal impairment
• medications/supplements that affect uric acid levels
• pregnant or lactating women
• prior history of allergic reaction to allopurinol or testing positive for HLA-B*5801 allele
• risk of urinary or gastric retention or narrow-angle glaucoma
• impaired hepatic function
• evidence of anemia
• evidence or diagnosis of congestive heart failure
• smokers
• subjects with a mutation other than rs2231142 in the ABCG2 genotype
• subjects taking hormonal contraceptives or other hormonal medications
• evidence of recreational drug use as determined by questionnaire